Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00228059 | An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder. | PHASE3 | COMPLETED | 132 | — | — | Jan 1, 2005 | Jul 1, 2007 | Feb 23, 2017 | 1 | United States |
| NCT00238485 | An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder | PHASE3 | COMPLETED | 251 | — | — | Jan 1, 2005 | Jul 1, 2007 | Mar 28, 2017 | - | — |
| Name | Type | Description |
|---|---|---|
| Licarbazepine | DRUG | - |
Inclusion Criteria: 1. written informed consent provided prior to participation in the extension study 2. successful completion of study CLIC477D2301 3. willingness and ability to comply with all study requirements Exclusion Criteria: 1. premature discontinuation from study CLIC477D2301 2. failur...